Dow Jones

39,512.84

0.00%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

KOD

Kodiak Sciences (KOD)

Kodiak Sciences Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:KOD

1 2 3 4 5 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
02/05/2024	15:30	PR Newswire (US)	Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform	NASDAQ:KOD	Kodiak Sciences Inc
28/03/2024	05:30	PR Newswire (US)	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:KOD	Kodiak Sciences Inc
26/03/2024	05:15	PR Newswire (US)	Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024	NASDAQ:KOD	Kodiak Sciences Inc
14/02/2024	15:23	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:KOD	Kodiak Sciences Inc
30/01/2024	05:30	PR Newswire (US)	Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting	NASDAQ:KOD	Kodiak Sciences Inc
04/01/2024	15:15	PR Newswire (US)	Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:KOD	Kodiak Sciences Inc
21/11/2023	15:15	PR Newswire (US)	Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:KOD	Kodiak Sciences Inc
14/11/2023	15:01	PR Newswire (US)	Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:KOD	Kodiak Sciences Inc
06/11/2023	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KOD	Kodiak Sciences Inc
06/11/2023	04:00	PR Newswire (US)	Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission	NASDAQ:KOD	Kodiak Sciences Inc
01/11/2023	22:21	PR Newswire (US)	KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING	NASDAQ:KOD	Kodiak Sciences Inc
11/10/2023	05:00	PR Newswire (US)	Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society	NASDAQ:KOD	Kodiak Sciences Inc
08/09/2023	05:00	PR Newswire (US)	Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	NASDAQ:KOD	Kodiak Sciences Inc
07/09/2023	05:00	PR Newswire (US)	New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion	NASDAQ:KOD	Kodiak Sciences Inc
14/08/2023	15:33	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KOD	Kodiak Sciences Inc
14/08/2023	15:01	PR Newswire (US)	Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:KOD	Kodiak Sciences Inc
24/07/2023	05:00	PR Newswire (US)	Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program	NASDAQ:KOD	Kodiak Sciences Inc
03/07/2023	15:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KOD	Kodiak Sciences Inc
27/06/2023	16:36	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:KOD	Kodiak Sciences Inc
07/06/2023	15:02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:KOD	Kodiak Sciences Inc
05/06/2023	05:07	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:KOD	Kodiak Sciences Inc
30/05/2023	15:15	PR Newswire (US)	Kodiak Sciences to Present at Upcoming Investor Conferences	NASDAQ:KOD	Kodiak Sciences Inc
15/05/2023	16:08	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:KOD	Kodiak Sciences Inc
15/05/2023	15:23	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:KOD	Kodiak Sciences Inc
15/05/2023	15:01	PR Newswire (US)	Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:KOD	Kodiak Sciences Inc
25/04/2023	15:46	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:KOD	Kodiak Sciences Inc
25/04/2023	15:05	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:KOD	Kodiak Sciences Inc
25/04/2023	15:02	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:KOD	Kodiak Sciences Inc
21/04/2023	06:30	PR Newswire (US)	Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting	NASDAQ:KOD	Kodiak Sciences Inc
03/04/2023	06:30	PR Newswire (US)	Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases	NASDAQ:KOD	Kodiak Sciences Inc